Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 28.50p 28.00p 29.00p 28.50p 28.50p 28.50p 6,000 07:45:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.6 -21.0 -17.0 - 33.09

Shield Therapeutics Share Discussion Threads

Showing 2676 to 2700 of 2700 messages
Chat Pages: 108  107  106  105  104  103  102  101  100  99  98  97  Older
DateSubjectAuthorDiscuss
18/5/2018
18:32
Technicals indicate a strong breakout from the down channel is underway. SHIELD THERAPEUTICS PLC has broken through the ceiling of a falling trend channel in the medium long term. This indicates a slower falling rate initially, or the start of a more horizontal development. Has risen strongly since the positive signal from a double bottom formation at the break through the resistance at 19.50. The objective at 23.50 is now met, but the formation still gives a signal in the same direction. The stock has resistance at pence 163p.
ny boy
18/5/2018
09:06
Steady as she goes Sir!
ny boy
17/5/2018
11:49
Some large buys showing, should see the share price up in the 30’s soon
ny boy
16/5/2018
14:49
A whole load of trades gone through @ 27p, buys or sells, no idea?
ny boy
16/5/2018
07:42
Looks more like a frying pan & handle, gentle rise into the year end!
ny boy
15/5/2018
15:50
Hilariously poor quality ramping aside - there is an interesting speculative bowl there with volume
luckymouse
14/5/2018
14:19
Looking for 110p+ if a bidder turns up but not in a hurry, let’s see how we go from here into year end
ny boy
13/5/2018
10:02
Must be a few secret buyers around, that don't post, usually a good sign.
ny boy
04/5/2018
10:43
Purchased a few now just in case it goes up
minky
04/5/2018
10:41
Seller done now, should start to move up quite rapidly, seems well over sold imho dyor as usual. Happy holding this year, will review mid 2019
ny boy
04/5/2018
10:27
I decided to invest here when STX announced their EU license expansion, to iron deficiency +/- anaemia. No mean achievement to get this, and gave me confidence in their regulatory team. I think they may even pull the NDA off as well for CKD - the FDA looks like they’re being pragmatic about the AEGIS-CKD Phase III study results – probably given the proven MoA. … Interesting to see the recent price movement - I guess initiated by SpreadEx buying up shares? Is this because there are a large number of long bets on their books? Sorry my knowledge of how spread betting companies work is not great.
pharma giles
03/5/2018
22:35
Just buy the physical shares the old fashioned way
ny boy
03/5/2018
08:40
IG Closing only will not allow BUY
minky
02/5/2018
18:23
Looks like major institutional seller has been cleared out - trades at 15.5 and 16 mostly yesterday and so the continual downward pressure has been relieved. If they have enough cash then shares are very cheap. If they get the FDA approval then very very cheap!
holiday6
02/5/2018
17:50
Was REDX on the list? They have hired the president of AstraZeneca as chief executive recently.Any others of note?
ohsod1t
02/5/2018
17:33
Peel Hunt identity Shield and a few others as possible bid targets, there is a feed on Twitter about it. Bodes well for some upside here imho
ny boy
02/5/2018
17:02
looks interesting
sux_2bu
02/5/2018
16:50
Me too.....looks like they are on the up. Finished on the high of the day without real news. Maybe something leaked to friends and family.
ohsod1t
02/5/2018
16:34
Yep I bought in today, one to hold and await further developments
ny boy
02/5/2018
09:29
Looks like twitter feeds are mentioning a potential take over target... wow, seriously under valued stock
rakepat37
02/5/2018
09:07
We should be sitting at 35p minimum with a up swing once news break with updates to 50p+
rakepat37
01/5/2018
16:01
Seriously undervalued stock and really hard to buy at the mo, took 10 mins to buy via phone. This will rise fast
rakepat37
13/4/2018
09:04
Been watching this for a while. Although positive news on expanded licence, the question for me also is what is going to trigger clinicians to prescribe the drug for general anaemia, given trials have only been with anaemia with CKD (failed) and IBD. And from what I gather it's more expensive. Surely they need to present evidence of how much better it would be for general anaemia otherwise why would the medical community take it up? Otherwise for now I'll wait to see what mngt say in the strategic review.
toadhall1
12/4/2018
22:49
Yes, the expanding licence is interesting; although the CEO states that the lack of promotional activity to enhance sales is going to inhibit this. Early days, but the slashing of the headcount may take time to get the former up-and-running again. Quite an alarming net loss, but patient uptake may kick in. Depends on the NHS price of the drug, as clinicians tend to favour equivalent, but less-expensive medication.
bobf1
12/4/2018
07:04
hxxps://www.chroniclelive.co.uk/business/business-news/gateshead-pharmaceutical-firm-reveals-big-14518892 Gateshead pharmaceutical firm reveals big price of failed US drug study Shield Therapeutics has been through a 'transformational' year pushing its iron deficiency drug Ferracru 15:35, 11 APR 2018 Full-year results from Gateshead pharm a firm Shield Therapeutics lay bare the high price of a drug study which has delayed its attempts to get into the lucrative US market, and resulted in “significant” job losses. The company announced in February it was significantly reducing its headcount to save cash after a study appeared to show its iron deficiency drug Ferracru had failed to reach trial targets needed to get into the US – wiping more than 85% off its market value. However, further analysis of the results of the study, which involved 168 patients, show they had been skewed by number of patient-specific events that the company believe adversely impacted the study. Now, following feedback from the American Food and Drug Administration (FDA), the firm is gearing up to submit a second application in the US to approve its main product. The high price of that first AEGIS-CKD study is laid bare in full year results posted by the AIM-listed company, however. Ferracru, Shield Therapeutics' main product Ferracru, Shield Therapeutics' main product (Image: Shield Therapeutics) The results, for the year ended December 31 2017, show plans to ramp up commercialisation of Ferracru in the UK and Europe were on track, with a strategy to take on 20 extra sales staff also on track. During the period, revenues doubled from £304,000 to £637,000 – the majority of which came from Europe – and Feraccru was out licensed across additional markets in Scandinavia and Switzerland. The firm has also now enlisted a third party to explore further options to grow in Europe. Shield’s net loss widened from £15m to £19.6m, primarily in relation to ongoing commercialisation and research and development activities, and selling costs also grew from £4.2m to £9.1m as commercial activities were developed in Europe. The results also show the AEGIS-CKD study and additional costs associated with the Marketing Authorisation Approval cost the business £4.7m. Chairman Andrew Heath paid tribute to staff who had been affected by the firm’s decision to slash the headcount. He said: “2017 was another year of solid progress for Shield, the results of which, however, have been significantly affected by post period events. “The board and I would like to thank all of Shield’s employees and its partners who have continued to show tremendous commitment and worked hard to deliver our corporate objectives and goals through a transformational period for the group. The decisions the board and management had to take immediately after receipt of the initial top-line results of the Phase III AEGIS-CKD study to reduce the operational activity and headcount of the business were particularly difficult, but completely necessary to protect our financial resources. “The board and I offer our sincere gratitude to all those who have been affected and who have shown continued commitment in difficult times.” CEO Carl Sterritt said the firm has been making progress in Germany and the UK and emphasised how Ferracru has big potential. He said: “Product awareness is growing, and more patients than ever are benefitting from Feraccru. During the first months of 2018 we have continued to see positive month-on-month growth in demand for Feraccru in both Germany and the UK. “With the approval of a broad label to treat iron deficiency, the potential for Feraccru to become a mainstay of therapy for patients with this debilitating condition is very real. “As a result of the company taking positive actions to preserve cash following the initial study top-line results reporting, the board believes that the company has sufficient cash resources to fund the business until at least the end of Q4 2018. “However, as this is being primarily achieved through a significant reduction in Shield’s own headcount and promotional activities related to Feraccru, with further cost containment remaining an ongoing priority, this is likely to impact sales of Feraccru. “However, we are evaluating ways of maintaining Feraccru’s share of voice in the marketplace to continue to build on the solid progress made to date.”
optrade
Chat Pages: 108  107  106  105  104  103  102  101  100  99  98  97  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20180521 03:17:08